Nektar Therapeutics Company Profile
NASDAQ: NKTRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Pre-market: 41.15 +0.86%
Nektar Therapeutics at a glance
Nektar Therapeutics (NASDAQ: NKTR) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in San Francisco, CA. Nektar Therapeutics is led by Mr. Howard W. Robin and employs about 63 people. At a market capitalization of $1.37 billion, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0000906709, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Nektar Therapeutics do?
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Business description based on the company's public filings.
Company information
- Legal name
- Nektar Therapeutics
- Ticker
- NASDAQ: NKTR
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Howard W. Robin
- Employees
- 63
- Headquarters
- 455 Mission Bay Boulevard South, San Francisco, CA, United States
- Phone
- 415 482 5300
- Website
- nektar.com
- Market cap
- $1.37B
- SEC CIK
- 0000906709
Companies similar to Nektar Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TYRATyra Biosciences Inc. | 19.97 | -2.06% | $1.37B | vs NKTR |
| ANABAnaptysBio Inc. | 46.21 | +1.23% | $1.38B | vs NKTR |
| OMEROmeros Corporation | 19.12 | +1.97% | $1.38B | vs NKTR |
| AAPGAscentage Pharma Group International American Depository Shares | 14.55 | -4.09% | $1.36B | vs NKTR |
| GHRSGH Research PLC | 20.45 | -2.90% | $1.40B | vs NKTR |
| KARDKardigan Inc. | 14.20 | +2.68% | $1.33B | vs NKTR |
| RAPPRapport Therapeutics Inc. | 29.85 | -3.27% | $1.43B | vs NKTR |
| PCRXPacira BioSciences Inc. | 36.39 | +44.40% | $1.45B | vs NKTR |